4 Biotechs Facing Do-or-Die Catalysts in December Post author:Sam Post published:December 5, 2017 Post category:BioPharma As 2018 winds down, it’s not over for some biopharma companies. Source: BioSpace You Might Also Like Merrimack Pharmaceuticals Expands Phase II Lung Cancer Study March 11, 2018 Ramaswamy's Roivant Inks $650M R&D Deal With This Tiny Diabetes Biotech February 11, 2018 INVO Bioscience Appoints Renowned Fertility Specialist To Its Board Of Directors April 10, 2017
